Search results
Showing 421 to 435 of 1300 results for heart OR cardi* OR arrythmia
How to register as a stakeholder with NICE.
Upadacitinib for treating moderately to severely active ulcerative colitis (TA856)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderately to severely active ulcerative colitis in adults.
Cytokine adsorption devices for treating respiratory failure in people with COVID-19 (MIB217)
NICE has developed a medtech innovation briefing (MIB) on cytokine adsorption devices for treating respiratory failure in people with COVID-19 .
patient selection, type and size of valve used, functional outcomes (New York Heart Association functional class, mitral valve...
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support.
This quality standard covers preventing bacterial infection in newborn babies, treating pregnant women and pregnant people whose babies are at risk of infection, and treating newborn babies with suspected or confirmed bacterial infection. It includes when to give antibiotics to prevent and treat neonatal bacterial infection and describes high-quality care in priority areas for improvement. This includes early-onset (within 72 hours of birth) and late-onset (between 72 hours and 28 days following birth) neonatal infection.
View quality statements for QS75Show all sections
Sections for QS75
- Quality statements
- Quality statement 1: Intrapartum antibiotics
- Quality statement 2: Assessment for early-onset neonatal infection
- Quality statement 3: Prompt antibiotic treatment for neonatal infection
- Quality statement 4: Reassessing antibiotic treatment for neonatal infection
- Quality statement 5: Information and support for parents and carers
- Update information
- About this quality standard
patient selection, type and size of valve used, functional outcomes (New York Heart Association functional class, mitral valve...
Angina and coronary heart disease: blood pressure (80 years and over) (IND242)
This indicator covers the percentage of patients aged 80 years or over with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12 months) is less than 145/85 mmHg if using ambulatory or home monitoring, or less than 150/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM226
Angina and coronary heart disease: blood pressure (79 years and under) (IND241)
This indicator covers the percentage of patients aged 79 years or under with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM225
NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .
Renal replacement therapy and conservative management (NG107)
This guideline covers renal replacement therapy (dialysis and transplantation) and conservative management for people with chronic kidney disease stages 4 and 5. It aims to improve quality of life by making recommendations on planning, starting and switching treatments, and coordinating care.
Evidence-based recommendations on percutaneous (non-thoracoscopic) epicardial catheter radiofrequency ablation for atrial fibrillation. This involves using heat to destroy selected areas of the heart to prevent the abnormal electrical impulses responsible for atrial fibrillation.
View recommendations for IPG294Show all sections
Sections for IPG294
NICE has developed a medtech innovation briefing (MIB) on CytoSorb therapy for sepsis .
Evidence-based recommendations on edoxaban (Lixiana) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.